Kurzporträt
- Onkologie (29,9%);
- Immunologie (17,2%);
- Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen (14,1%);
- Neurologie (8,9%).
Der restliche Umsatz (29,9%) wird aus der Auftragsfertigung von Pharmaprodukte erzielt.
Ende 2023 verfügte die Novartis AG über 33 Produktionsstandorte auf der ganzen Welt.
Die geographische Umsatzverteilung sieht aus wie folgt: Europa (33%), USA (39,5%), Asien / Afrika / Australasien (20,5%), Kanada und Lateinamerika (7%).
Mitarbeiterzahl: 76 057
Umsatz nach Geschäftsbereich
CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Established Brands
30,0
%
| - | - | 12 238 | 30,0 % | - |
Oncology
29,9
%
| - | - | 12 213 | 29,9 % | - |
Immunology
17,2
%
| - | - | 7 008 | 17,2 % | - |
Cardiovascular, Renal and Metabolic
14,1
%
| - | - | 5 743 | 14,1 % | - |
Neuroscience
8,9
%
| - | - | 3 633 | 8,9 % | - |
Umsatz je Region
CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
39,5
%
| 16 860 | 34,9 % | 16 139 | 39,5 % | -4.28% |
Europe
18,9
%
| 10 469 | 21,7 % | 7 704 | 18,9 % | -26.41% |
Asia/Africa/Australasia
9,1
%
| 4 975 | 10,3 % | 3 700 | 9,1 % | -25.63% |
Germany
7,4
%
| 4 086 | 8,5 % | 3 026 | 7,4 % | -25.94% |
China
7,2
%
| 2 987 | 6,2 % | 2 936 | 7,2 % | -1.73% |
Canada and Latin America
7,0
%
| 3 709 | 7,7 % | 2 854 | 7,0 % | -23.04% |
Japan
4,2
%
| 2 106 | 4,4 % | 1 729 | 4,2 % | -17.90% |
France
3,8
%
| 2 156 | 4,5 % | 1 572 | 3,8 % | -27.09% |
Switzerland
2,9
%
| 926 | 1,9 % | 1 175 | 2,9 % | +26.88% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 48 | 01.01.05 | |
Director of Finance/CFO | 59 | 01.01.03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16.05.22 |
Steffen Lang
COO | Chief Operating Officer | 57 | 01.04.17 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 01.12.18 |
Samir Shah
IRO | Public Communications Contact | 63 | 01.01.04 |
Simon Brown
PRN | Corporate Officer/Principal | - | 01.08.13 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 01.05.22 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 01.09.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01.01.13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28.02.20 |
Chairman | 68 | 01.01.13 | |
John Young
BRD | Director/Board Member | 60 | 07.03.23 |
Bridgette Heller
BRD | Director/Board Member | 62 | 28.02.20 |
Ton Büchner
BRD | Director/Board Member | 59 | 01.01.16 |
Charles Sawyers
BRD | Director/Board Member | 65 | 01.01.13 |
Nancy Andrews
BRD | Director/Board Member | 65 | 01.01.15 |
Patrice Bula
BRD | Director/Board Member | 68 | 28.02.19 |
Frans van Houten
BRD | Director/Board Member | 64 | 28.02.17 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 2 189 930 497 | 1 866 336 959 ( 85,22 %) | 233 443 766 ( 10,66 %) | 85,22 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
NOVARTIS AG 6,63% | 145 083 991 | 6,63% | 14 073 485 173 $ |
SANDOZ GROUP AG 4,30% | 18 524 209 | 4,30% | 559 613 390 $ |
MORPHOSYS AG 11,57% | 4 360 100 | 11,57% | 316 438 618 $ |
NOVARTIS INDIA LIMITED 70,68% | 17 450 680 | 70,68% | 215 208 068 $ |
ERASCA, INC. 8,15% | 12 307 692 | 8,15% | 25 353 846 $ |
THIRD HARMONIC BIO, INC. 6,49% | 2 642 762 | 6,49% | 24 947 673 $ |
OCULIS HOLDING AG 4,68% | 1 713 521 | 4,68% | 20 647 928 $ |
5 908 089 | 6,12% | 18 846 804 $ | |
MOLECULAR PARTNERS AG 4,78% | 1 739 130 | 4,78% | 7 095 929 $ |
413 577 | 6,30% | 5 608 104 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis BioVenturesAG
Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The private company is based in Basel, Switzerland. |
Investment Managers
|
Pharmaceuticals: Major
| |
Novartis Securities Investment Ltd.
Novartis Securities Investment Ltd. Investment ManagersFinance Part of Novartis AG, Novartis Securities Investment Ltd. is an investment bank that offers investment advice. The private company is located in Bermuda. |
Investment Managers
|
EBEWE Pharma Ges.m.b.H. Nfg.KG
EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria. |
Pharmaceuticals: Major
|
Novartis Capital Corp.
Novartis Capital Corp. Finance/Rental/LeasingFinance Novartis Capital Corp. engages in the manufacture of pharmaceutical products. The company is headquartered in East Hanover, NJ. |
Finance/Rental/Leasing
|
Novartis Finance SA
|
Finance/Rental/Leasing
|
Sandoz GmbH
Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. |
Pharmaceuticals: Major
|
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
% 1. Jan. | Kap. | |
---|---|---|
+21.85% | 546 Mrd. | |
-4.77% | 359 Mrd. | |
+16.97% | 323 Mrd. | |
+5.69% | 290 Mrd. | |
+13.68% | 234 Mrd. | |
-11.12% | 194 Mrd. | |
+8.08% | 167 Mrd. | |
-3.40% | 157 Mrd. | |
+1.72% | 123 Mrd. |